10-KPeriod: FY2025

REGENERON PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2025

Filed February 4, 2026For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. reported solid financial performance for the fiscal year ending December 31, 2025, with revenues reaching $14.34 billion and net income at $4.50 billion. The company's strategic focus on scientific innovation and integrated development, manufacturing, and commercialization capabilities continues to drive growth. Key products like Dupixent and EYLEA HD demonstrated strong performance, contributing significantly to the company's top-line results, despite increased competition and the ongoing transition from EYLEA to EYLEA HD. The company also highlighted its robust pipeline with numerous product candidates in various stages of clinical development across multiple therapeutic areas, including ophthalmology, immunology, oncology, and rare diseases. Regeneron continues to invest heavily in research and development to fuel future growth. However, investors should be aware of potential headwinds. The company is heavily reliant on its flagship products, EYLEA and Dupixent, and faces significant competition, including from biosimilars for EYLEA. Regulatory and manufacturing challenges were noted, particularly concerning a third-party manufacturer (Catalent) that led to delays in FDA approvals for EYLEA HD's pre-filled syringe and Ordspono. The company is actively managing these issues by onboarding new manufacturers and addressing regulatory feedback. The evolving healthcare landscape, including pricing pressures and potential regulatory changes, also presents risks that investors should monitor.

Financial Highlights

48 data points
Beta

Revenue

$14.34B

Net Income

$4.50B

31.4% Net Margin

EPS (Diluted)

$41.48

Total Assets

$40.56B

Cash & Equivalents

$3.12B

Free Cash Flow

$4.98B

Financial Statements
Beta
Revenue$14.34B
R&D Expenses$5.85B
SG&A Expenses$2.70B
Operating Expenses$10.77B
Operating Income$3.58B
Net Income$4.50B
EPS (Basic)$43.07
EPS (Diluted)$41.48
Shares Outstanding (Basic)104.60M
Shares Outstanding (Diluted)108.60M

Key Highlights

  • 1Regeneron reported revenues of $14.34 billion and net income of $4.50 billion for the fiscal year ending December 31, 2025, showing growth from the previous year.
  • 2Dupixent continues to be a major growth driver, with Sanofi collaboration revenue (primarily from Dupixent) increasing by over 29% to $5.88 billion.
  • 3EYLEA HD and EYLEA combined U.S. net product sales were $4.38 billion, a decrease from 2024, impacted by competitive pressures and the transition to EYLEA HD.
  • 4The company experienced delays in the approval of EYLEA HD's pre-filled syringe and Ordspono due to issues identified during a third-party manufacturer's FDA inspection, which the company is actively addressing.
  • 5Regeneron's R&D expenses increased by approximately 14% to $5.85 billion, reflecting continued investment in its extensive pipeline of product candidates.
  • 6The company maintained a strong balance sheet with $3.12 billion in cash and cash equivalents and $15.40 billion in marketable securities as of December 31, 2025.
  • 7Regeneron initiated a quarterly cash dividend program in 2025, signaling a commitment to returning capital to shareholders.

Frequently Asked Questions

Regeneron's revenue growth in 2025 was primarily driven by strong performance in collaboration revenue, particularly from Dupixent and Kevzara through the Sanofi collaboration. Regeneron's share of profits from these products increased significantly, contributing to the overall revenue growth. Net product sales of EYLEA HD also saw an increase, although this was offset by a decline in EYLEA sales due to increased competition and market dynamics.

Key risks for investors include Regeneron's substantial dependence on EYLEA and Dupixent for revenue, facing significant competition and biosimilar threats for EYLEA. Manufacturing and regulatory hurdles, specifically issues with a third-party manufacturer impacting approvals for EYLEA HD and Ordspono, are also critical concerns. Additionally, the evolving healthcare landscape, including pricing pressures and potential regulatory changes, alongside the inherent uncertainties in drug development, are important factors for investors to monitor.

Regeneron is actively addressing the issues stemming from third-party manufacturing inspections. For EYLEA HD's pre-filled syringe, the company has submitted a new regulatory application with a different manufacturer and expects an FDA decision in Q2 2026. Similarly, for Ordspono, the company is working with the FDA to resolve the issues cited in the Complete Response Letter (CRL) that were related to the manufacturing observations.

Regeneron maintains a robust R&D strategy, heavily investing in its proprietary technologies like VelociSuite and its Regeneron Genetics Center. The company has a diverse pipeline with numerous product candidates in clinical development across various therapeutic areas. Notable late-stage programs include fianlimab for oncology, lynvoseltamab and ordonextamab for hematology, and garetosmab for fibrodysplasia ossificans progressiva (FOP). The company also continues to advance Dupixent for new indications and is developing novel therapies for eye diseases, inflammation, and rare genetic disorders.